18 June 2013
Keywords: Ligand Pharma, Chiva Pharma, Fablyn, Osteoporosis, Global license
Article | 12 October 2011
In a second deal with the company, Ligand Pharmaceuticals (Nasdaq: LGND) has entered into a global licensing agreement with Chiva ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 October 2011
11 October 2011
13 October 2011
© 2013 thepharmaletter.com